Dharwad News Today

Propulsion of Metastatic Colorectal Cancer Clinical Trial Pipeline as Novel and Extensive 130+ Therapies Likely to Enter in the Domain | DelveInsight

 Breaking News
  • No posts were found

Propulsion of Metastatic Colorectal Cancer Clinical Trial Pipeline as Novel and Extensive 130+ Therapies Likely to Enter in the Domain | DelveInsight

August 26
05:25 2023
Propulsion of Metastatic Colorectal Cancer Clinical Trial Pipeline as Novel and Extensive 130+ Therapies Likely to Enter in the Domain | DelveInsight

(Albany, United States) As per DelveInsight’s assessment, globally, the Metastatic Colorectal Cancer Pipeline constitutes 130+ key companies continuously working towards developing 140+ Metastatic Colorectal Cancer Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.

 

In the Metastatic Colorectal Cancer Pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, Metastatic Colorectal Cancer NDA approvals (if any), and product development activities comprising the technology, Metastatic Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

To explore more information on the latest breakthroughs in the Metastatic Colorectal Cancer Pipeline treatment landscape of the report, click here @ Metastatic Colorectal Cancer Pipeline Outlook

 

Key Takeaways from the Metastatic Colorectal Cancer Pipeline Report

  • DelveInsight’s Metastatic Colorectal Cancer Pipeline analysis depicts a robust space with 130+ active players working to develop 140+ pipeline treatment therapies.
  • The leading companies working in the Metastatic Colorectal Cancer Market include Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, enentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
  • Promising Metastatic Colorectal Cancer Pipeline Therapies in the various stages of development include ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009, Trifluridin/Tipiracil, and others.
  • On August 2023, K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc announced a study of phase 1 & 2 clinical trials for ZN-c3, Encorafenib, and Cetuximab. The purpose of this study is to evaluate the safety, tolerability, and potential clinical benefits of ZN-c3 administered in combination with encorafenib and cetuximab in adult participants with metastatic BRAF V600E mutant colorectal cancer previously treated with one or two treatment regimens.
  • On August 2023, Arcus Biosciences Inc. announced a study of phase 1 & 2 clinical trials for AB680, Etrumadenant, Zimberelimab, and Regorafenib. This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer.

 

Metastatic Colorectal Cancer Overview

Cancer cells may break away from a tumor in the colon or rectum and spread to other parts of the body through the bloodstream or lymphatic system. These cells may settle and form new tumors on a different organ.

 

For further information, refer to the detailed Metastatic Colorectal Cancer Unmet Needs, click here for Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis

 

Metastatic Colorectal Cancer Emerging Drugs Profile

  • Adagrasib (MRTX849): Mirati Therapeutics
  • QL-1203: Qilu Pharmaceutical
  • ZN-c3: Zentalis Pharmaceuticals

 

Metastatic Colorectal Cancer Pipeline Therapeutics Assessment

There are approx. 130+ key companies which are developing the therapies for Metastatic colorectal cancer. The companies which have their Metastatic colorectal cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.

 

Request a sample and discover the recent advances in Metastatic Colorectal Cancer Ongoing Clinical Trial Analysis and Medications, Click here for more details @ Metastatic Colorectal Cancer Segmentation

 

Metastatic Colorectal Cancer Drugs and Companies

  • Cetuximab: Pfizer
  • CMAB009 plus Irinotecan: Shanghai Zhangjiang Biotechnology Limited Company
  • Trifluridin/Tipiracil: Servier Deutschland GmbH

 

Metastatic Colorectal Cancer Therapeutics Assessment

  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

 

Some of the Companies in the Metastatic Colorectal Cancer Therapeutics Market include-

Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, enentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.

 

Dive deep into rich insights for drugs for Metastatic Colorectal Cancer Pipeline, click here @ Metastatic Colorectal Cancer Unmet Needs and Analyst Views

 

Scope of the Metastatic Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Companies- Mirati Therapeutics, Shanghai Zhangjiang Biotechnology Limited Company, Genor Biopharma Co., Ltd., Menarini Group, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Arcus Biosciences, Inc., SFJ Pharmaceuticals, Merck Serono, Sumitomo Pharma Co., Ltd., Immunovative Therapies, Ltd., Cardiff Oncology, Symphogen A/S, enentech, Qilu Pharmaceutical Co., Ltd., Henlix Biotech, Scandion Oncology A/S, Aadi Bioscience, Inc., Novartis, Roche, Boehringer Ingelheim, Isofol Medical, Treos Bio, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Elevar Therapeutics, Shanghai Henlius Biotech, and others.
  • Therapies- ZN-c3, Encorafenib, Cetuximab, CMAB009 plus Irinotecan, Irinotecan-only and sequential-CMAB009, Trifluridin/Tipiracil, and others.
  • Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Metastatic Colorectal Cancer Merger and acquisitions, Licensing Activities

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Metastatic colorectal cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Metastatic colorectal cancer – DelveInsight’s Analytical Perspective
  7. In-depth Commercial Assessment
  8. Metastatic colorectal cancer Collaboration Deals
  9. Late Stage Products (Phase III)
  10. MRTX849: Mirati Therapeutics
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. AK-112: Akeso Biopharma
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. SY 5609: Syros Pharmaceuticals
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug name: Company name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Metastatic colorectal cancer Key Companies
  23. Metastatic colorectal cancer Key Products
  24. Metastatic colorectal cancer- Unmet Needs
  25. Metastatic colorectal cancer- Market Drivers and Barriers
  26. Metastatic colorectal cancer- Future Perspectives and Conclusion
  27. Metastatic colorectal cancer Analyst Views
  28. Metastatic colorectal cancer Key Companies
  29. Appendix

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services